Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €49.80 EUR
Change Today -0.43 / -0.86%
Volume 2.9K
NOVA On Other Exchanges
Symbol
Exchange
OTC US
Copenhagen
New York
Mexico
Frankfurt
Frankfurt
As of 11:29 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

novo-nordisk a/s-spons adr (NOVA) Snapshot

Open
€49.32
Previous Close
€50.23
Day High
€50.78
Day Low
€48.89
52 Week High
08/6/15 - €56.06
52 Week Low
10/16/14 - €32.50
Market Cap
129.5B
Average Volume 10 Days
5.8K
EPS TTM
--
Shares Outstanding
2.1B
EX-Date
03/19/15
P/E TM
--
Dividend
€0.77
Dividend Yield
1.38%
Current Stock Chart for NOVO-NORDISK A/S-SPONS ADR (NOVA)

Related News

No related news articles were found.

novo-nordisk a/s-spons adr (NOVA) Details

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. The company markets and distributes its products through its subsidiaries, distributors, and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

39,658 Employees
Last Reported Date: 08/6/15
Founded in 1925

novo-nordisk a/s-spons adr (NOVA) Top Compensated Officers

Chief Executive Officer, President and Member...
Total Annual Compensation: kr15.2M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: kr8.1M
Chief Science Officer, Executive Vice Preside...
Total Annual Compensation: kr8.1M
Chief of Staff, Executive Vice President and ...
Total Annual Compensation: kr5.5M
Executive Vice President of China, Pacific & ...
Total Annual Compensation: kr5.5M
Compensation as of Fiscal Year 2013.

novo-nordisk a/s-spons adr (NOVA) Key Developments

Novo Nordisk Adds $1.85 Billion Expansion

Novo Nordisk is adding a projected $1.85 billion expansion and doubling its workforce of 700 at its 22-year-old Clayton campus in Johnston County. The new facility will expand the company's ability to produce ingredients for current and future diabetes-fighting products when it begins operation in 2020. Novo Nordisk also announced plans to establish a new $800 million production facility in Mllrv, Denmark for tableting and packaging of oral products. The investment in Mllrv will create an estimated 100 new jobs. The expansion announced puts the company in line for up to $15.9 million in state incentives upon meeting agreed-upon hiring and investment milestones. The new jobs will pay an average $68,420. That's nearly twice the Johnston County average wage, though less than the statewide life science average of $81,000.

Novo Nordisk to Invest $1.2 Billion

Novo Nordisk will build a $1.2 billion manufacturing facility in Johnston County and add 691 jobs there in the coming five years.

Novo Nordisk to Invest $2 Billion in New Production Facilities in North Carolina and Denmark

Novo Nordisk A/S announced that it plans to invest an estimated $2 billion over the next five years in new production facilities in Clayton, North Carolina and Malov, Denmark to support the increasing demand for diabetes medicine. The final design and cost of the planned production facilities will be presented to the company's board in 2016, and the facilities are expected to be operational during 2020.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOVA:GR €49.80 EUR -0.43

NOVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $63.98 USD -0.53
Allergan plc $308.01 USD -3.99
Amgen Inc $155.89 USD +0.17
Bristol-Myers Squibb Co $60.61 USD -0.21
Eli Lilly & Co $83.19 USD -0.55
View Industry Companies
 

Industry Analysis

NOVA

Industry Average

Valuation NOVA Industry Range
Price/Earnings 30.9x
Price/Sales 9.7x
Price/Book 24.5x
Price/Cash Flow 24.5x
TEV/Sales 7.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVO-NORDISK A/S-SPONS ADR, please visit www.novonordisk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.